Building a drug–target network and its applications

Background: One of the most recent and important developments in drug discovery is a new drug development approach of building and analyzing networks that contain relationships among drugs and targets, diseases, genes and other components. These networks and their integrations provide useful information for finding new targets as well as new drugs. Objective: This review article aims to review recent developments in various types of networks and suggest the future direction of these network studies for drug discovery. Methods: Databases and networks are integrated into a more complete network to better present the relationships among drugs, targets, genes, phenotypes and diseases. After discussing the limitations and obstacles of the recent research, we suggest several strategies to build a successful and practical drug–target network. Results/conclusion: A useful, integrated network can be built from various databases and networks by resolving several issues, such as limited coverage and inconsistency. This integrated network can be completed by the prediction of missing links, biological network comparison and drug target identification. Possible applications are multi-target drug development, drug repurposing, estimation of drug effect on target perturbations in the whole system and extraction of the suitable purpose of the drug–target sub-network.

[1]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[2]  V. McKusick Mendelian inheritance in man , 1971 .

[3]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[4]  M. Kanehisa,et al.  A heuristic graph comparison algorithm and its application to detect functionally related enzyme clusters. , 2000, Nucleic acids research.

[5]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[6]  M. Vidal,et al.  Identification of potential interaction networks using sequence-based searches for conserved protein-protein interactions or "interologs". , 2001, Genome research.

[7]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[8]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[9]  A. Barabasi,et al.  Hierarchical Organization of Modularity in Metabolic Networks , 2002, Science.

[10]  R. Karp,et al.  Conserved pathways within bacteria and yeast as revealed by global protein network alignment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Joshua M. Stuart,et al.  A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules , 2003, Science.

[13]  Yu Zong Chen,et al.  Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.

[14]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[15]  John D. Westbrook,et al.  TargetDB: a target registration database for structural genomics projects , 2004, Bioinform..

[16]  Roded Sharan,et al.  Revealing modularity and organization in the yeast molecular network by integrated analysis of highly heterogeneous genomewide data. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Ball Theatre: Playing dirty , 2004, Nature.

[18]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[19]  T. Hampton,et al.  "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. , 2004, JAMA.

[20]  Peter D. Karp,et al.  MetaCyc: a multiorganism database of metabolic pathways and enzymes , 2005, Nucleic Acids Res..

[21]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[22]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[23]  Michael Lässig,et al.  Local graph alignment and motif search in biological networks. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Gerstein,et al.  Annotation transfer between genomes: protein-protein interologs and protein-DNA regulogs. , 2004, Genome research.

[25]  C. Wermuth,et al.  Multitargeted drugs: the end of the "one-target-one-disease" philosophy? , 2004, Drug discovery today.

[26]  Wojciech Szpankowski,et al.  An efficient algorithm for detecting frequent subgraphs in biological networks , 2004, ISMB/ECCB.

[27]  G. Church,et al.  Modular epistasis in yeast metabolism , 2005, Nature Genetics.

[28]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[29]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[30]  Simon K. Mencher,et al.  BMC Clinical Pharmacology BioMed Central Debate , 2005 .

[31]  R. Karp,et al.  From the Cover : Conserved patterns of protein interaction in multiple species , 2005 .

[32]  U. Alon,et al.  Spontaneous evolution of modularity and network motifs. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[34]  S. Frantz Drug discovery: Playing dirty , 2005, Nature.

[35]  R P Araujo,et al.  A mathematical model of combination therapy using the EGFR signaling network. , 2005, Bio Systems.

[36]  L. M. Espinoza-Fonseca,et al.  The benefits of the multi-target approach in drug design and discovery. , 2006, Bioorganic & medicinal chemistry.

[37]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[38]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[39]  Sourav Bandyopadhyay,et al.  Systematic identification of functional orthologs based on protein network comparison. , 2006, Genome research.

[40]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[41]  T. Ideker,et al.  Modeling cellular machinery through biological network comparison , 2006, Nature Biotechnology.

[42]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[43]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[44]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[45]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[46]  Mike Tyers,et al.  BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..

[47]  Chemical combination effects predict connectivity in biological systems , 2007, Molecular systems biology.

[48]  Yi Wang,et al.  DITOP: drug-induced toxicity related protein database , 2007, Bioinform..

[49]  Jianwen Fang,et al.  The reactive metabolite target protein database (TPDB) – a web-accessible resource , 2007, BMC Bioinformatics.

[50]  Luhua Lai,et al.  Prediction of potential drug targets based on simple sequence properties , 2007, BMC Bioinformatics.

[51]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[52]  M. Gerstein,et al.  What is a gene, post-ENCODE? History and updated definition. , 2007, Genome research.

[53]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[54]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[55]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[56]  Helen E. Parkinson,et al.  ArrayExpress—a public database of microarray experiments and gene expression profiles , 2006, Nucleic Acids Res..

[57]  Benjamin A. Shoemaker,et al.  Deciphering Protein–Protein Interactions. Part I. Experimental Techniques and Databases , 2007, PLoS Comput. Biol..

[58]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[59]  Jerzy Tiuryn,et al.  Identification of functional modules from conserved ancestral protein-protein interactions , 2007, ISMB/ECCB.

[60]  Humberto González Díaz,et al.  Unified QSAR and network‐based computational chemistry approach to antimicrobials, part 1: Multispecies activity models for antifungals , 2008, J. Comput. Chem..

[61]  Benjamin A. Shoemaker,et al.  Deciphering Protein–Protein Interactions. Part II. Computational Methods to Predict Protein and Domain Interaction Partners , 2007, PLoS Comput. Biol..

[62]  Yasubumi Sakakibara,et al.  Statistical prediction of protein-chemical interactions based on chemical structure and mass spectrometry data , 2007, Bioinform..

[63]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[64]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[65]  Mona Singh,et al.  Organization of Physical Interactomes as Uncovered by Network Schemas , 2008, PLoS Comput. Biol..

[66]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[67]  Marcel J. T. Reinders,et al.  Metabolic pathway alignment between species using a comprehensive and flexible similarity measure , 2008, BMC Systems Biology.

[68]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[69]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[70]  P. Bork,et al.  Large‐scale prediction of drug–target relationships , 2008, FEBS letters.

[71]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[72]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[73]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[74]  Stefan Günther,et al.  SuperPred: drug classification and target prediction , 2008, Nucleic Acids Res..

[75]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[76]  Dongsup Kim,et al.  Inference of Protein Complex Activities from Chemical-Genetic Profile and Its Applications: Predicting Drug-Target Pathways , 2008, PLoS Comput. Biol..

[77]  Michael Schroeder,et al.  Unraveling Protein Networks with Power Graph Analysis , 2008, PLoS Comput. Biol..

[78]  Jean-Marc Schwartz,et al.  A global view of drug-therapy interactions , 2007, BMC pharmacology.

[79]  Hiroki Kobayashi,et al.  Integrating Statistical Predictions and Experimental Verifications for Enhancing Protein-Chemical Interaction Predictions in Virtual Screening , 2009, PLoS Comput. Biol..

[80]  Julie M. Sahalie,et al.  An experimentally derived confidence score for binary protein-protein interactions , 2008, Nature Methods.

[81]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[82]  Alessandra Carbone,et al.  Joint Evolutionary Trees: A Large-Scale Method To Predict Protein Interfaces Based on Sequence Sampling , 2009, PLoS Comput. Biol..

[83]  K. Chou,et al.  Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. , 2009, Bioorganic & medicinal chemistry.

[84]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[85]  Eugenio Uriarte,et al.  Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. , 2009, Molecular pharmaceutics.

[86]  Alan F. Scott,et al.  McKusick's Online Mendelian Inheritance in Man (OMIM®) , 2008, Nucleic Acids Res..

[87]  Xin Guo,et al.  Domain-oriented edge-based alignment of protein interaction networks , 2009, Bioinform..

[88]  Keunwan Park,et al.  Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. , 2009, Molecular bioSystems.

[89]  Jordi Mestres,et al.  A chemogenomic approach to drug discovery: focus on cardiovascular diseases. , 2009, Drug discovery today.